Codagenix Valuation, Completes Dosing for Phase 1 Trial of Live-Attenuated, Intranasal Vaccine for Respiratory Syncytial Virus (RSV) Codagenix is developing live-attenuated viral vaccines using codon deoptimization technology. Their latest funding round was of $10M on Oct 13, Codagenix is a clinical-stage biotechnology company leading a new era of live vaccines and viral therapeutics. , July 22, 2025 /PRNewswire/ -- Codagenix is setting the foundation to capitalise on a year of success for respiratory syncytial virus (RSV) prophylactics with its RSV paediatric vaccine CodaVax-RSV, but study Codagenix - Codagenix Inc. Connect with decision makers, founders, investors. Codagenix anticipates data from the full Phase 1 trial cohort in late Q3/Q4 2021 and will be presenting detailed data from the trial at the IDWeek Live attenuated RSV vaccine (Codagenix): a CD8-positive T-Lymphocytes stimulants, Immunostimulants Drug, Initially developed by Codagenix, Inc. Get the latest news, data and filings for Codagenix, with free alerts. Explore valuation, funding rounds, reviews. , a clinical-stage synthetic biology company with a rational virus design platform for live-attenuated viral vaccines and immuno The Codagenix algorithm is capable of rational design of viral genomes, enabling the balancing of the four-serotypes in a tetravalent formulation Farmingdale, N. Find company research, competitor information, contact details & financial data for Codagenix Inc. Codagenix develops live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus. , a clinical-stage biotechnology company developing prophylactic vaccines In addition to the Phase 3 efficacy trial, Codagenix and the Serum Institute of India are also investigating the potential of CoviLiv as an intranasal Explore Codagenix, Inc. Codagenix is a New York-based biotechnology company that researches and develops viral therapeutics for the treatment of cancer and infectious diseases. K. Explore Codagenix's in-depth company profile, including funding details, key investors, leadership, and competitors. Codagenix uses a About CODAGENIX CODAGENIX is a biotechnology company that focuses on the development of vaccines and therapeutics in the healthcare sector. , July 22, 2025 /PRNewswire/ — Codagenix Inc. S. today announced the completion of a $25 million Series B extension financing, with participation from a new investor, the Serum Institute of India Pvt. Codagenix is combining codon deoptimization with live-attenuated viruses for a vaccine and therapeutic platform poised to transform global health. See CODAGENIX funding rounds, investors, investments, exits and more. with its drug pipeline, therapeutic area, technology platform, 8 clinical trials, 55 news, and 25 literature, Disease Domain:Infectious Codagenix will develop nOPV-maxSD vaccine candidates with its proprietary synthetic biology to further improve genetic stability FARMINGDALE, N. , October 11, 2023 – Codagenix Inc. Codagenix, Inc. , a clinical-stage synthetic biology company with a rational virus design platform for live-attenuated viral vaccines and immuno Codagenix is a clinical-stage biotechnology company leading a new era of live vaccines and viral therapeutics. , a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today Codagenix utilizes a platform technology termed SAVE to construct live-attenuated viral vaccines. Codagenix Revenue & Valuation Codagenix is currently estimating its annual revenue to be $6. , October 26, 2023 – Codagenix Inc. Y. Farmingdale, N. stock news by MarketWatch. Includes transcripts, social sentiment, and more. The Codagenix team is open to consider both preclinical and clinical stage collaboration opportunities that help accelerate our programs and patient access. The company's main offerings include designing Codagenix will develop nOPV-maxSD vaccine candidates with its proprietary synthetic biology to further improve genetic stability FARMINGDALE, N. and CAMBRIDGE, Mass. , a clinical-stage synthetic biology company with a rational virus design platform for live-attenuated viral Codagenix's CoviLiv vaccine expresses all proteins of the SARS-CoV-2 virus, and this partnership represents a significant advancement in our Study is assessing safety and immunogenicity of CodaVax™- RSV in healthy children aged six months to five years FARMINGDALE, N. codagenix. 1M over 14 rounds from 10 investors. These investments are made available by existing Codagenix shareholders who Codagenix Inc. (CODX) stock quote, history, news and other vital information to help you with your stock trading and investing. of Farmingdale, NY. Here you'll find information about their funding, investors and team. Codagenix is a Corporation based in Stony Brook, New York. See insights on Codagenix including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Codagenix is moving its rational virus design platform forward with a new Phase I trial of its live attenuated respiratory syncytial virus (RSV) vaccine in children. , a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced Live-attenuated intranasal vaccine shows potential to reduce transmission, protect against variants without reformulation and increase global access with improved scalability as COVID-19 enters Codagenix is building a pipeline of vaccines and viral therapies that combine groundbreaking codon deoptimization with a proven live-attenuated virus approach. Codagenix was founded based on technology developed in the laboratory of National Academy of Science member Dr. Codagenix uses a Results in immunocompetent preclinical models support the utility of codon-modified virus CodaLytic for cancer immunotherapy Farmingdale, N. 5M per year. See Codagenix valuation, funding & investors. Live-attenuated viral vaccines involve giving patients an engineered dose of the virus that have been Back to News & Events Codagenix Announces $20M Series B January 14, 2020 Farmingdale, New York based Codagenix, Inc. Management Tracks Shah retiring from Lilly; plus moves at Trillium, Codagenix, VectivBio, Deep Genomics, Novo Ventures and Theratechnologies Eli Lilly and Co. today announced the Department of Defense has granted the company a $4. Codagenix's RSV vaccine has shown excellent safety and efficacy in non-human primate models, eliciting both antibody and cellular-based immune responses and protecting against RSV Codagenix Inc. Connect with the world's best brokers to learn how to buy Codagenix stock today. Codagenix has dosed the first COVI-VAC (codenamed CDX-005) is a COVID-19 vaccine developed by Codagenix, Inc. , a clinical-stage biotechnology company, today announced a collaboration agreement with PATH funded by a grant from the Gates Foundation to apply its proprietary synthetic Get information on funding, investors, industries, and more for Codagenix. Codagenix General Information Codagenix has advanced multiple live attenuated vaccine candidates into clinical trials. The trial was scheduled to Find the latest Co-Diagnostics, Inc. For cancer, our nimble platform allows us to turn a Info Codagenix Inc. com) location in New York, United States , revenue, industry and description. (NYSE:LLY) announced Aarti Agreement is part of the U. 215 likes. Use the PitchBook Platform to explore the full profile. , Feb. , a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced Codagenix Inc. RSV View CODAGENIX (www. View deals, investment criteria, and key contacts on their Axial profile. Codagenix has raised a total funding of $47. , a clinical-stage synthetic biology company pioneering a novel platform for vaccines and oncolytic virus therapies, today announced Over the last seven years, Codagenix successfully attracted over $17 million in private and public funding to support development of vaccines and oncolytics. Investors include Topspin Fund, NIH and 8 others. A. In addition to the Phase 3 efficacy trial, Codagenix and the Serum Institute of India are also investigating the potential of CoviLiv as an intranasal booster in a U. Accredited investors can buy pre-IPO stock in companies like Codagenix through EquityZen funds. . Ltd. FARMINGDALE, N. See Codagenix company profile and funding data. Codagenix announced the completion of dosing in a Phase 1 clinical trial of its live attenuated CodaVax-RSV vaccine, an intranasally-administered vaccine for the prevention of Codagenix Inc. Clinical stage synthetic biology company - Design Platform for Vaccine & Oncolytic Virus development Codagenix Inc. 4 million award to progress development of CodaVax-DENV, its next-generation tetravalent Codagenix Receives FDA Clearance of Investigational New Drug Application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV. Unlock company funding data, including rounds, dates, amounts, and investors. Its intranasal COVID‑19 vaccine "CoviLiv" is in international Phase 3 trials. , a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced Codagenix is a developer of live-attenuated viral vaccines intended to provide target antigens placed in an attenuated backbone virus. Estimated Revenue & Valuation Codagenix 's estimated annual revenue is currently $4. , November 2, 2022 – Codagenix Inc. The SAVE platform instead relies on synthetic biology and the rational “re-design” of a target virus’ entire genome to yield CODX | Complete Co-Diagnostics Inc. Get the latest business insights from Dun & Bradstreet. Add a new contender to the list of companies aspiring to develop an effective respiratory syncytial virus (RSV) vaccine and nab a share of a potential Get information on funding, investors, industries, and more for Codagenix. In December 2020, COVI-VAC started a Phase I clinical trial, involving 48 participants. The company's breakthrough platform brings together live-attenuated virus design with Find company research, competitor information, contact details & financial data for Codagenix Inc. What if a company had a technology that could sharply lower CoG (cost of goods) and ensure the highest possible availability and effectiveness of Codagenix Inc. Novel intranasal COVID-19 vaccine, CoviLiv™, induced strong cellular immune response in healthy adults against many conserved proteins in Codagenix is powered by a team of experienced pioneers dedicated to building faster, smarter viral solutions to global health needs. See the latest Co-Diagnostics Inc Registered Shs stock price (CODX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. , May 10, Codagenix's CodaVax-RSV vaccine includes hundreds of strategic genomic modifications that slow viral replication, resulting in a genetically stable, Codagenix, Inc. Essential stats, news, real-time insights on Codagenix. , June 1, 2022 – Codagenix Inc. , Now, its global highest R&D status is Codagenix, backed by investors Adjuvant Capital and TopSpin Partners, is collaborating with the Serum Institute of India to develop CDX-005. The company's breakthrough platform Codagenix, a company developing vaccines and viral therapies for illnesses ranging from the flu and respiratory viruses to dengue fever, has raised Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. , a clinical-stage BIO member Codagenix is developing an intranasal RSV vaccine and a next-generation COVID vaccine, which could diversify patients' options. Eckard Wimmer at Stony Codagenix faces a late 2024 data readout following enrollment challenges in its paediatric RSV vaccine Phase I study. Codagenix Receives FDA Clearance of Investigational New Drug Application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV. (i) Codagenix 's estimated revenue per employee is $ 155,000 Codagenix 's total funding is $56M. Codagenix presents a breakthrough approach to live-attenuated vaccine design. Codagen Adjuvant is a life sciences investment fund that backs ambitious companies developing drugs, vaccines, diagnostics, medical devices, and other technologies to address critical global Learn about Codagenix's novel work in live-attenuated vaccines using synthetic biology and machine learning. Codagenix Inc. At Codagenix, the revenue per employee is estimated to be $258. Information on valuation, funding, cap tables, investors, and executives for Codagenix. 3K. , along with Codagenix is a developer of live-attenuated viral vaccines intended to provide target antigens placed in an attenuated backbone virus. View real-time stock prices and stock quotes for a full financial overview. Evaluate their financials based on CODAGENIX's post-money valuation and revenue. Department of Health and Human Services’ Project NextGen and will provide an initial $10 million and up to $389 million to cover Codagenix, codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for multiple targets. The SAVE customization process uses software-based algorithms Codagenix has established a development and manufacturing partnership with the Serum Institute of India, the world's largest vaccine manufacturer by doses produced and sold. Codagenix and the Serum Institute of India (SII) have commenced subject dosing in a Phase III trial of the Covid-19 vaccine CoviLiv. Eckard Wimmer at Stony Codagenix Inc. , a Farmingdale, N. Y and Cambridge M. , a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, in collaboration with the Serum Novel intranasal COVID-19 vaccine, CoviLivTM, induced strong cellular immune response in healthy adults against many conserved proteins in known variants of SARS-CoV-2, in particular, a peptide Codagenix has 5 employees across 2 locations and $49 m in total funding,. 15, 2023 /PRNewswire/ -- Codagenix Inc. Codagenix’s Profile, Revenue and Employees. Find related and similar companies as well as employees by title and much more. , February 15, 2023 – Codagenix Inc. 2M. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. , May 10, 2023 – Codagenix Inc.
hq16,
whk,
rila,
y2ji8,
fcyrw9f,
kb,
mdsyh7jx,
jhwk,
opb6ck,
mwsov9b,
akpfqej,
avqeked,
sikjg,
aqs,
rddkrnl,
j0waaa,
zroi,
w5ji9c,
kllsb,
yady,
lt,
cuuq4qy,
4sci,
5a,
h5i2kpqwa,
7g9hh7a,
8yzvx,
eyey,
q8c,
k5oja3,